Side by side
Compare companies
Line up to six companies across valuation, growth, profitability, leverage, ownership and technicals. Best and worst per row are highlighted.
| Metric | TORNTPHARM | ZYDUSLIFE | LAURUSLABS | MANKIND | AUROPHARMA |
|---|---|---|---|---|---|
| Size & Price | |||||
| Market capitalisation | ₹1,61,325 Cr | ₹1,14,284 Cr | ₹1,07,176 Cr | ₹1,04,696 Cr | ₹97,389 Cr |
| Enterprise value | ₹1,76,123 Cr | ₹1,26,053 Cr | ₹1,09,573 Cr | ₹1,11,007 Cr | ₹1,05,065 Cr |
| Revenue (TTM) | ₹15,723 Cr | ₹28,592 Cr | ₹7,270 Cr | ₹14,738 Cr | ₹34,935 Cr |
| EBITDA (TTM) | ₹5,191 Cr | ₹8,316 Cr | ₹2,034 Cr | ₹3,827 Cr | ₹7,085 Cr |
| PAT (TTM) | ₹2,181 Cr | ₹4,513 Cr | ₹1,093 Cr | ₹2,068 Cr | ₹3,713 Cr |
| Current price | ₹4,767.30 | ₹1,145.70 | ₹1,984.00 | ₹2,535.00 | ₹1,676.80 |
| 1-day change | -0.68% | -1.4% | +0.2% | +1.25% | +0.29% |
| Avg volume (30d) | — | — | — | — | — |
| 52-week high | — | — | — | — | — |
| 52-week low | — | — | — | — | — |
| Distance from 52w high | — | — | — | — | — |
| Distance from 52w low | — | — | — | — | — |
| Valuation | |||||
| Price to earnings | 74.0× | 25.3× | 98.0× | 50.6× | 26.2× |
| Price to book | 19.2× | 4.3× | 20.2× | 6.4× | 2.6× |
| Price to sales | 10.3× | 4.0× | 14.7× | 7.1× | 2.8× |
| EV / EBITDA | 33.9× | 15.2× | 53.9× | 29.0× | 14.8× |
| Dividend yield | 0.92% | 1.05% | 0.14% | 0.04% | 0.24% |
| Earnings yield | 1.35% | 3.95% | 1.02% | 1.97% | 3.81% |
| PEG ratio | 3.66 | 0.68 | 24.5 | 3.55 | 1.19 |
| Book value / share | ₹248.2 | ₹269.5 | ₹98.2 | ₹394.9 | ₹652.4 |
| EPS (TTM) | ₹64.5 | ₹44.9 | ₹20.3 | ₹50.1 | ₹63.9 |
| Growth | |||||
| Sales growth (1y) | 21.4% | 16.8% | 22.7% | 17% | 6.1% |
| Sales growth (3y CAGR) | 13.3% | 16.3% | 4.1% | 17.7% | 10.6% |
| Sales growth (5y CAGR) | 11.8% | 12.4% | 7.2% | — | 6.3% |
| Profit growth (1y) | 13.2% | 3,326.2% | 148% | -3.7% | 0.5% |
| Profit growth (3y CAGR) | 20.2% | 37% | 4% | 14.3% | 22.1% |
| Profit growth (5y CAGR) | 11.6% | 18.8% | -2% | — | -8.1% |
| Qtr sales growth (YoY) | 54.8% | 22% | 29.1% | 12.9% | 16.3% |
| Qtr profit growth (YoY) | 3.3% | -34.9% | 123.9% | 29.1% | 25.2% |
| Profitability | |||||
| Operating margin | 32.6% | 31.2% | 26.1% | 25.3% | 20.3% |
| Net margin | 15.3% | 18.9% | 13.1% | 13.6% | 10.4% |
| Return on equity | 27.1% | 19.7% | 18.2% | 12.5% | 9.9% |
| Return on capital employed | 14.5% | 23.4% | 21.3% | 14.2% | 14.7% |
| Return on assets | 4.8% | 9.8% | 8.5% | 6.9% | 6% |
| ROE (3y avg) | 26.3% | 7% | 10.2% | 17.3% | 10.8% |
| ROCE (3y avg) | 23.8% | 23.4% | 14% | 19.9% | 15.7% |
| Leverage & Quality | |||||
| Debt to equity | 1.76 | 0.43 | 0.45 | 0.39 | 0.2 |
| Interest coverage | 8.7× | 17.3× | 7.9× | 4.8× | 14.5× |
| Current ratio | 1.13 | 1.27 | 1.33 | 1.1 | 1.81 |
| Working capital days | 163 | 212 | 263 | 117 | 252 |
| Ownership | |||||
| Promoter holding | 68.3% | 75% | 27.5% | 72.6% | 51.9% |
| Promoter pledge | 0% | 0% | 0% | 0% | 0% |
| FII holding | 15.4% | 6.9% | 28% | 9.5% | 16.4% |
| DII holding | 9.7% | 11.3% | 13.7% | 15.4% | 25.1% |
| Public holding | 6.4% | 6.8% | 30.8% | 2.5% | 6.6% |
| Promoter holding change (1y) | 0% | 0.02% | -0.12% | -0.05% | 0.06% |
| Technical | |||||
| 50-day moving average | — | — | — | — | — |
| 200-day moving average | — | — | — | — | — |
| Price vs 50 DMA | — | — | — | — | — |
| Price vs 200 DMA | — | — | — | — | — |
| RSI (14) | — | — | — | — | — |
| Return (1m) | — | — | — | — | — |
| Return (3m) | — | — | — | — | — |
| Return (6m) | — | — | — | — | — |
| Return (1y) | — | — | — | — | — |
| Return (3y CAGR) | — | — | — | — | — |
| Relative strength (1y) | — | — | — | — | — |
| Volatility (1y) | — | — | — | — | — |
| Beta | — | — | — | — | — |
best in row weakest in rowRows without a better/worse direction aren't highlighted.